

# Ongoing & Planned Trials of Intermittent Pre-Exposure Prophylaxis (i-PrEP)

December 9, 2009

---

## International AIDS Vaccine Initiative (IAVI)

- IAVI E001/E002: safety and acceptability of intermittent dosing (vs. daily dosing) of Pre-exposure Prophylaxis (PrEP), Truvada (TDF/FTC) in Kenya and Uganda. Currently enrolling men & women age 18-49, with an expected total enrollment of 150 participants.

IAVI Description:

<http://www.iavi.org/research-development/trials/Pages/PrEPstudy.aspx>,

IAVI Q&A:

<http://www.iavi.org/about-IAVI/careers/Documents/PrEP%20QA%20FOR%20WEB.pdf>

- Information on clinicaltrials.gov:

<http://clinicaltrials.gov/ct2/show/NCT00971230>

<http://clinicaltrials.gov/ct2/show/NCT00931346>

## HIV Prevention Trials Network (HPTN)/CDC

These trials are still in the design and planning stages. Below is a summary of some of the likely attributes of two intermittent trials being developed.

- HPTN 066: Intensive pharmacokinetics (PK) study evaluating Truvada (TDF/FTC) anogenital secretion and tissue concentrations after different dosing strategies. Total number of participants to be approximately 60. Study to be conducted in the US only.
- HPTN 067: High risk women and MSM in high incidence areas, to assess acceptability and adherence of fixed interval vs. coitally-dependent iPrEP. Total number of participants to be approximately 360. Study to be conducted in different countries, likely Thailand and select African countries.